Evidence map›Paper›PMID 36969903›Full record

ArticleJournal of clinical and translational hepatology2023

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-

Yun Beom Sang, Gwangil Kim, Sohyun Hwang, Haeyoun Kang, Hong Jae Chon

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and translational hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Precision models in hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. [Expert consensus for clinical application of molecular diagnosis on hepatobiliary tumors (2024 edition)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  9. [The regulation of APGAT4 on the growth and lenvatinib resistance of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yun Beom SangDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam-si, Gyeonggi-do, Korea.ORCID https://orcid.org/0000-0002-1123-6313
Gwangil KimDepartment of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam-si, Gyeonggi-do, Korea.ORCID https://orcid.org/0000-0002-4867-9003
Sohyun HwangDepartment of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam-si, Gyeonggi-do, Korea.ORCID https://orcid.org/0000-0003-2461-6806
Haeyoun KangDepartment of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam-si, Gyeonggi-do, Korea.ORCID https://orcid.org/0000-0002-8980-7702
Hong Jae ChonDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam-si, Gyeonggi-do, Korea.ORCID https://orcid.org/0000-0002-6979-5812
CHA University Bundang Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of a patient with c-

Indexed as

Cabozantinibc-MET amplificationDramatic responseHepatocellular carcinomaNext-generation sequencing

Identifiers

PMID36969903
PMCPMC10037501
OpenAlexW4293716673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.